Long-Term (104 Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials
Services
Services
Date issued
2015Journal title
Arthritis and Rheumatology
Type of content
Publicación de congreso
